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Fabry_CEP is a user-friendly web-application designed to help clinicians Choose Eligible Patients for the therapy
with pharmacological chaperones. It provides a database and a predictive tool to evaluate the responsiveness
of lysosomal alpha-galactosidase mutants to a small molecule drug, namely 1-Deoxy-galactonojirimycin. The
user can introduce any missense/nonsense mutation in the coding sequence, learn whether it is has been
tested and gain access to appropriate reference literature. In the absence of experimental data structural,
functional and evolutionary analysis provides a prediction and the probability that a given mutation is
responsive to the drug.
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Pharmacological chaperones (PC) offer a promising
therapeutic strategy for Fabry disease (FD). Most experi-
ments have focused on 1-deoxy-galactonojirimycin, also
known as DGJ, migalastat-hydrochloride or AT1001.
The decision to use it in therapy has to be taken on a
case-by-case basis after precise genotyping because DGJ
is not effective on all alpha-galactosidase (AGAL) mu-
tants. Thirteen out of 450 missense/nonsense mutations
[1] have been tested in clinical trials [2,3] and 130 in
cells (for a review [4]). Fabry_CEP [5] helps finding
experimental data for a given mutation. The reference
sequences for wild-type (EMBL: X05790 or UniProt:
AGAL_HUMAN for the open reading frame or for
amino-acid sequence, respectively) are provided and the
substitute nucleotide or amino acid can be selected. If
experimental data are available, the user will get an an-
swer taken from the literature to whether the mutation
is responsive to DGJ. A non-sense mutation gener-
ates a truncated protein which is not amenable for
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reproduction in any medium, provided the orDisruption of a disulphide bond or occurrence into the
active site (as defined in [6]) are the only structural
features sufficient, but not necessary, to prevent re-
sponsiveness to DGJ. When these conditions occur,
Fabry_CEP [5] gives a negative outcome. The structure
of wild-type AGAL is displayed with the residues in-
volved in disulphide bridges highlighted in yellow and
those of the active site in blue. Upon selection, the site
affected by the mutation is shown on a space-filling
model and colored in yellow or in blue, if it occurs at di-
sulphide bridge sites or in the active site, in magenta
otherwise. Recently, it was proposed that mutations
promoting protein aggregation do not respond to PC
[7]. We ran the program TANGO [8] and we found that
a small minority, twelve out of 130 mutations experi-
mentally tested Fabry, is predicted to promote aggrega-
tion. Indeed mutations with high TANGO score tend to
be non responsive, but the condition is neither neces-
sary nor sufficient to prevent responsiveness.
If a mutation does not occur in the active site and
does not disrupt disulphide bonds, Fabry_CEP [5] usesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Performance of Fabry_CEP illustrated by receiver
operating characteristic (ROC) curve.






























Figure 1 Correlation of responsiveness to pharmacological
chaperones with scores assigned with a Position Specific
Substitution Matrix (PSSM).
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[9]. In brief the method considers the degree of conserva-
tion and the type of amino acid introduced at the site of
the mutation. For these mutations an outcome can be
given only in probabilistic terms. We re-evaluated the cor-
relation between PSSM scores and the percentage of re-
sponsive mutations tested experimentally for this subset
of cases (113). We obtained a Pearson correlation coeffi-
cient r = 0.92 with two-tailed p-value 0.01 (Figure 1).
AGAL contains a signal peptide of 31 aa. Although
a PSSM score might be calculated also for mutations
occurring in this peptide, we prefer to not give a con-
clusion because there are no experimental data in this
region to benchmark the prediction.
The complete test-set used to build Fabry_CEP [5]
falls in nine discrete rating categories. We built the
receiver operating characteristic (ROC) curve shown
in Figure 2 and measured empiric and fitted ROC
Areas, 0.807 and 0.825 respectively.
Figure 3 illustrates a representative case analyzed by
Fabry_CEP [5] with a upper section for the query, a
middle section for the intermediate results on which
the conclusion is drawn and a lower section with the
section showing the final outcome.
Private mutations are common in Fabry disease and
missense mutations are very common, so it is expected
that this tool may progressively gain more importance
in the future. However a word of caution is needed.
Fabry_CEP [5] can be used as a predictive tool, but its
clinical applicability is limited and individual decisions
on whether to start or not DGJ should not be based
solely on this tool.
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